tradingview.comOct 28$CHE

Chemed Corp Stock 12‑Month Price Target Raised to $592.6, Implies 16% Upside

Chemed Corp's (CHE) average price target increased to $592.6 from $571.6, with a range of $548 to $650, implying 16% upside. Analysts' consensus rating shifted to 'Buy' with 3 Buys, 2 Holds, and 1 Sell.

Original reporting

tradingview.com

Published Oct 28, 2026, 10:20 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 28, 2026, 10:27 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Chemed Corp Stock 12‑Month Price Target Raised to $592.6, Implies 16% Upside — source image — Source · tradingview.com

Decision brief

The 30-second read

$CHEBullishLow

Why it matters

Analyst consensus shift to Buy and higher targets may attract interest, but impact is modest without new operational news.

Market read

Small upward pressure expected; not a catalyst for broader market moves.

What to watch

Potential regulatory or reimbursement changes could affect outlook.

Relevance 6/10Novelty 5/10Timing: today

Background

Chemed Corp is a provider of specialty health care services; price target updates are common analyst activity.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CHEBullishMedium confidence

Context

Analyst consensus raised price target to $592.6, implying ~16% upside.

Expected impact

likely modest buying pressure as investors price in upside

Evidence & confidence

New target reflects improved expectations; no immediate catalyst beyond analyst revisions.

Market effects

Sector

None significant; Chemed operates in healthcare services.

Regional

Limited to US healthcare sector.

Global

Low

Counterpoint

What could challenge this read

Target raise may be premature if earnings miss expectations.

Key entities

company
Chemed Corp
US-listed healthcare services provider (ticker CHE).

Read at source ← All news

$CHEMedAI 9/10

Chemed 3Q 2026: Revenue $690.9M, EPS $5.45— 10-Q Summary

Chemed reported Q3 2026 revenue of $690.9M, up 10.6% YoY, with net income rising 11.5% to $71.6M and EPS increasing 22.2% to $5.45. Growth in VITAS and Roto-Rooter segments drove results, while higher fuel costs pressured margins. The company acquired RotoCo and other franchises, expanding its territories.

tradingview.comOct 29

$CHEMed

What Chemed (CHE) Said on Its Q3 Earnings Call

Chemed reported Q3 earnings, with Roto-Rooter revenue up 7.5% but EBITDA down 2.5% due to higher costs. Commercial revenue grew 9% to $59.9M, while residential rose 5.2% to $158.8M. The company acquired California franchises for $62.5M, expecting $30M-$35M in 2027 revenue but less than $4M in EBITDA. Chemed repurchased 125,000 shares for $66M. Management expects 2026 EPS to meet or slightly exceed guidance.

finance.yahoo.comOct 29

$CHEHigh

Chemed Corp (CHE) Q3 2026 Earnings Call Highlights: VITAS Strength Drives 28% EPS Growth

Chemed Corp (CHE) reported Q3 2026 earnings with VITAS driving 28% EPS growth. Roto-Rooter saw a 2.5% EBITDA decline due to higher marketing and fuel costs. VITAS faces regulatory audits, reviewing $12-$14M in revenue. Chemed anticipates continued cost headwinds in Q4. Management discussed hiring, acquisitions, and lead generation strategies.

finance.yahoo.comOct 28

$CHEMed

Chemed outlines 12- to 18-month integration timeline for $62.5M California Roto-Rooter franchise buyback while expecting 2026 EPS at or slightly above prior high end (NYSE:CHE)

Chemed (CHE) announced a 12- to 18-month integration timeline for its $62.5M California Roto-Rooter franchise buyback. CEO Kevin McNamara reported VITAS revenue grew 12.2% year-over-year, driven by ADC growth and cost containment. The company expects 2026 EPS to be at or slightly above the prior high end.

seekingalpha.comOct 28

$CHEHighAI 8/10

Chemed (CHE) Q3 2026 Earnings Call Transcript

Chemed (CHE) reported Q3 2026 earnings with total revenue up 10.6% and adjusted EPS up 28.1% YoY. VITAS saw 12.2% revenue growth, while Roto Rooter grew 7.5%. Roto Rooter's margins declined due to higher marketing costs and fuel expenses, but acquisitions are expected to drive long-term growth. The company has $229M in cash flow from operations, enabling strategic acquisitions and share repurchases.